<code id='CA253B1DA5'></code><style id='CA253B1DA5'></style>
    • <acronym id='CA253B1DA5'></acronym>
      <center id='CA253B1DA5'><center id='CA253B1DA5'><tfoot id='CA253B1DA5'></tfoot></center><abbr id='CA253B1DA5'><dir id='CA253B1DA5'><tfoot id='CA253B1DA5'></tfoot><noframes id='CA253B1DA5'>

    • <optgroup id='CA253B1DA5'><strike id='CA253B1DA5'><sup id='CA253B1DA5'></sup></strike><code id='CA253B1DA5'></code></optgroup>
        1. <b id='CA253B1DA5'><label id='CA253B1DA5'><select id='CA253B1DA5'><dt id='CA253B1DA5'><span id='CA253B1DA5'></span></dt></select></label></b><u id='CA253B1DA5'></u>
          <i id='CA253B1DA5'><strike id='CA253B1DA5'><tt id='CA253B1DA5'><pre id='CA253B1DA5'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:focus    Page View:6
          Bruce Broussard. -- health business coverage from STAT
          Humana CEO Bruce Broussard Jason DeCrow/AP

          Bruce Broussard, CEO of health insurance giant Humana, will step down next year after leading the company for more than a decade.

          Humana named Jim Rechtin — who is the CEO of Envision Healthcare, the controversial physician staffing firm that is working its way through bankruptcy — as Broussard’s replacement. Rechtin will serve as president and chief operating officer starting Jan. 8 and then take over as CEO in the “latter half of 2024,” the company said in a news release.

          advertisement

          Humana’s stock fell by more than 2% on the news Wednesday morning.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M
          Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

          CytokineticsCEORobertBlumspokelastweekatatalkduringSTAT’sBreakthroughSummitWestinSanFrancisco.SarahG

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          Congressmen charge Covid hearing ‘could have been an email’

          Rep.BradWenstrup(R-Ohio)AnnaMoneymaker/GettyImagesWASHINGTON—HouseRepublicanshaverepeatedlyaccusedBi